Using MRD as a clinical endpoint “will enable drug approval through a special, accelerated pathway that could shave years off the process,” says C. Ola Landgren, MD, PhD, director of Sylvester’s Myeloma Research Institute, who led the analysis behind a recent FDA committee vote.